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Abstract
Purpose: Selecting patients with metastatic clear-cell renal cell
carcinoma (m-ccRCC) who might benefit from treatment with
targeted tyrosine kinase inhibitors (TKI) is a challenge. Our aim
was to identify molecular markers associated with outcome in
patients with m-ccRCC treated with sunitinib.
Experimental Design: We performed global transcriptome
analyses on 53 primary resected ccRCC tumors from patients
who developed metastatic disease and were treated with first-line
sunitinib. We also determined chromosome copy-number
aberrations, methylation status, and gene mutations in von Hip-
pel–Lindau and PBRM1. Molecular data were analyzed in relation
with response rate (RR), progression-free survival (PFS), andoverall
survival (OS). Validation was performed in 47 additional ccRCC
samples treated in first-line metastatic setting with sunitinib.
Results: Unsupervised transcriptome analysis identified 4
robust ccRCC subtypes (ccrcc1 to 4) related to previous molec-
ular classifications that were associated with different responses
to sunitinib treatment. ccrcc1/ccrcc4 tumors had a lower RR
(P ¼ 0.005) and a shorter PFS and OS than ccrcc2/ccrcc3
tumors (P ¼ 0.001 and 0.0003, respectively). These subtypes
were the only significant covariate in the multivariate Cox
model for PFS and OS (P ¼ 0.017 and 0.006, respectively).
ccrcc1/ccrcc4 tumors were characterized by a stem-cell poly-
comb signature and CpG hypermethylation, whereas ccrcc3
tumors, sensitive to sunitinib, did not exhibit cellular response
to hypoxia. Moreover, ccrcc4 tumors exhibited sarcomatoid
differentiation with a strong inflammatory, Th1-oriented but
suppressive immune microenvironment, with high expression
of PDCD1 (PD-1) and its ligands.
Conclusions: ccRCC molecular subtypes are predictive of
sunitinib response in metastatic patients, and could be used for
personalized mRCC treatment with TKIs, demethylating or
immunomodulatory drugs. Clin Cancer Res; 21(6); 1329–39. 2015
AACR.
Introduction
Targeted therapies (TT) have significantly improved the prog-
nosis of patients with metastatic clear-cell renal cell carcinoma
(m-ccRCC). Sunitinib is a tyrosine kinase inhibitor (TKI) targeting
VEGFR that significantly prolongs progression-free survival (PFS),
but not overall survival (OS), as compared with IFNa (1, 2).
Currently, it is an approved first-line treatment option for patients
with m-ccRCC. However, in the pivotal phase III trial, 7% of
patients experience progressive disease (PD) upon RECIST at their
first evaluation, and virtually all patients ultimately develop PD
(2). In routine clinical practice, primary PD rate is higher andmay
reach 20%. Although several prognostic factors of survival in
patients with m-ccRCC receiving TT have been described and
several resistance mechanisms have been proposed (3), no reli-
able biomarkers of sunitinib sensitivity or primary/secondary
resistance have been identified.
Recent unsupervised gene expression analysis of 48 ccRCCs
identified two molecular ccRCC subtypes (ccA and ccB; ref. 4). A
meta-analysis of 480 ccRCCs confirmed this classification and
identified a third subtype, cluster_3, associated with a wild-type
von Hippel–Lindau (VHL) gene profile (5). The Cancer Genome
Atlas (TCGA) project subsequently highlighted four ccRCC
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subtypes (6). In both studies, postnephrectomy survival was
related to ccRCC subtype. A poor prognosis was also associated
with somatic mutations in BAP1 and SETD2 (7, 8) and with
chromosome amplifications or losses at 8q, 14q, or 9p (9–12).
However, no associations have been made between molecular
features and outcome in patients with m-ccRCC on TT (13).
We hypothesized that an integrated genomic analysis of
primary ccRCCs might help to identify subgroups of ccRCCs
more sensitive or resistant to anti-VEGFR TT. Thus, the aim of
our study was to determine whether expression profiles, geno-
mic abnormalities, mutational status, and epigenetic changes




Primary ccRCC specimens were collected from 121 patients
undergoing nephrectomy in 19 French and one Belgian hospitals
from 1994 to 2011 (patient characteristics in Supplementary
Table S1). For inclusion in the study, patients had to have
developed synchronous ormetachronicmetastases, received suni-
tinib (50mg/day, 4weeks on/2weeks off) asfirst-line treatment in
the metastatic setting (prior cytokine therapy was allowed),
completed at least one 28-day cycle of sunitinib, and undergone
their first CT scan assessment.
Drug schedule and dose-reduction policy complied with
local practice guidelines. Follow-up chest/abdomen CT scans
were performed every 2 cycles of treatment. Study endpoints
were response rate (RR) according to RECIST 1.0, PFS, and OS.
Four expert genitourinary pathologists blinded to patient out-
come reviewed all nephrectomy pathology slides. The protocol
was approved by the medical ethics review boards of all
participating institutions. Signed consent was obtained from
all patients in accordance with French and Belgian legislations.
Frozen biologic material from deceased patients was used when
prior agreement for such use had been given by the institutional
review board.
Datasets and preprocessing
Dataset for transcriptome (E-MTAB-3267), SNP (E-MTAB-3269)
and methylome (E-MTAB-3274) are available at ArrayExpress
(https://www.ebi.ac.uk/arrayexpress/).
Transcriptome data. Transcriptomic profilingwasperformedusing
HuGene 1.0ST Affymetrix array for 53 ccRCC samples and 6
adjacent normal tissue samples (NT). Biotinylated single-strand
cDNA targets were prepared with 200 ng of total RNA, using the
Ambion WT Expression Kit and the GeneChip WT Terminal
Labeling Kit according to Affymetrix recommendations.
Methylome data.Whole-genome DNA methylation was analyzed
in 102 ccRCCs and 5 adjacent NTs using the Illumina Infinium
HumanMethylation450 assay that examines the DNA methyla-
tion status of 485.000 CpG sites (covering 99% of RefSeq genes
and 96% of CpG islands).Genomic DNA was extracted using
either the Manual-MagNa Pure LC DNA II Kit (Roche) or the
Manual-Gentra Puregene Kit (Qiagen) and bisulfite-converted
using the EZ-96 DNA Methylation Kit (Zymo Research) by Inte-
gragen SA (http://www.integragen.com) and processed according
to the Illumina protocol.
Genome data. For chromosome gain/loss profiling, 103 ccRCCs
and 5 adjacent NTs were analyzed with Illumina OmniExpress
chips, containing 731.442 probes. Hybridization was performed
by IntegraGen, according to the manufacturer's instructions. The
absolute copy numbers and genotype status of segments were
determined using the genome alteration print (GAP) method
(14). Segmentswith an absolute copy number above (respectively
below) the ploidy of the sample were considered as gains (respec-
tively losses). TheGenomic Identification of Significant Targets In
Cancer (GISTIC) methodology (15) was used to identify signif-
icantly recurrent chromosome aberrations.
Quantitative RT-PCR. qRT-PCR reactions were performed on 98
ccRCCs and 5 NTs with low density array (LDA) for 65 genes and
individual probes for 5 genes as previously described (16). Genes
were selected from the differential analysis of the Affymetrix data
(ANOVA q-value less than 0.05 and an absolute fold change
greater than 1.5). Primers and probes for all genes were obtained
from Applied Biosystems Taqman Gene Expression Assays. Sup-
plementary Table S2 provides the gene symbol, gene name, and
Applied Biosystems Assay ID number for the genes studied.
For details onoverlap between samples used for eachomics, see
Supplementary Table S3.
Mutation analysis
Tumors were screened for VHL and PBRM1 mutations (Sup-
plementary Table S4) using direct sequencing (primers and pro-
tocols available on request).
Omics analysis
Unsupervised classification. For unsupervised class discovery with-
in the four omics, three methods were used: the recursively
partitioned mixture model (RPMM; ref. 17) and two consensus
clustering methods (18, 19). Only the results obtained with the
third method were described in the article. Nevertheless, we
showed a strong association between the three methods (Fisher
exact P values from 3.9e–19 to 2.92e–21). We used the gap
statistic to determine the number of clusters (20).
Translational Relevance
After 10 years of routine clinical use of tyrosine kinase
inhibitors (TKI) in metastatic clear-cell renal cell carcinoma
(m-ccRCC), the selection of patients who might benefit from
this treatment remains a challenge. In this translational work,
based on a large series of fresh-frozen kidney tumor samples
combinedwith an extended clinical database, we have defined
four robustmolecular subtypes ofm-ccRCC significantly asso-
ciatedwith different responses to sunitinib. Thiswork not only
provides the first integrative genomic study of m-ccRCC but it
also identifies subtypes of tumors resistant to sunitinib and
associated with poor survival. These molecular subtypes of
tumors are characterized by a stem-cell polycomb signature, a
CpG hypermethylation, sarcomatoid differentiation, and a
strong inflammatory, Th1-oriented but suppressive immune
microenvironment. These new molecular signatures could be
used for a more personalized m-ccRCC treatment to admin-
istrate TKIs, demethylating or immunomodulatory drugs,
according to the molecular typing of the tumors.
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Differential analysis. We used moderate T tests to identify genes
differentially expressed between groups of samples, using limma
R-package. ANOVA models were used for multigroup compari-
son. To control for multiple testing, we measured the local FDR
using the Benjamini and Hochberg method (R-package stats).
Association analysis.We evaluated the association between unsu-
pervised or supervised subgroups and the bioclinical factors using
c2 or Fisher exact test. For each clinical characterization, all
covariates were analyzed but only the significant covariates were
shown (P 0.05). The bioclinical factors included tumor–node–
metastasis, Eastern Cooperative Oncology Group Performance
Status (ECOG-PS), InternationalMetastatic RenalCell Carcinoma
Database Consortium (IMDC), Fuhrman, or Memorial Sloan
Kettering Cancer Center (MSKCC) scores, systemic treatment,
hemoglobin (<11.5 g/dL inwomen, <13.0 g/dL inmen), platelets
(>400,000/mm3), lactate dehydrogenase (>1.5 upper limit of
normal), neutrophils (>4,500/mm3), calcium (>10mg/dL), path-
ologic characteristics such as eosinophils, necrosis, or inflamma-
tion, rhabdoid, and sarcomatoid phenotypes.
Fisher exact or c2 tests were used to select the recurrent chro-
mosome aberrations identified by GISTIC that are differential
between groups. Criteria of sensitivity and specificity were added
to select aberrations characteristic of a given subgroup. An aber-
ration was characteristic of a given subgroup if the sensitivity and
the specificity are >0.65.
Signaling pathway analysis. To identify biologic features associ-
ated with ccRCC molecular subtypes, 17,306 pathways collected
fromKEGG, GO,MSigDB, SMD, and Biocarta (and related genes)
were tested. A hypergeometric test was used to measure the
association between a gene (probe set) list—related to a given
molecular subtype (see below)—and a biologic pathway or a gene
ontology term (GO term), as in GOstats R-package from R.
Gentleman. Pathway analyses were performed on transcriptome
data, methylome data, and methylome data anticorrelated with
transcriptome data (correlation test P  0.05 and correlation
coefficient <0). In this pathways analysis, the gene lists related
to each molecular subtypes corresponded to (i) genes specifically
upregulated in the subtype (respectively hypermethylated), (ii)
genes specifically downregulated in the subtype (respectively
hypomethylated), and (iii) genes both up and downregulated
(respectively hyper- and hypomethylated) in the subtype.
Survival analysis. Survival time was calculated from the first
sunitinib treatment. Patients who were lost to follow-up or alive
at the time of the study were treated as censored events. Survival
curves were calculated according to the Kaplan–Meier method
(function Surv, R-package survival, V2.29), and differences
between curves were assessed using the log-rank test (function
survdiff, R-package survival).
To find clinical criteria related to PFS or OS, univariate models
were performed on all the pathologic and clinical covariates (func-
tion coxph, R-package survival). Covariates showing a significant
association to prognosis (log-rank P < 0.05) at the univariate level
were selected to be analyzed in multivariate models, after the
exclusion of redundant covariates (ex MSKCC- and IMDC scores).
Classifier building. The training set was composed of 51 samples
with Affymetrix and qRT-PCR, and the validation set was com-
posed of 47 samples with only qRT-PCR.
A first centroid-based predictor was built to assign a sample to
one of the three following groups ccrcc1&4/ccrcc2/ccrcc3 using a
subset of the differentially expressed genes between these three
groups. A gene was defined differentially expressed in a subtype
when the ANOVA P value was <0.05 and when the absolute fold
changewith the other subtypeswas>0.5. The optimal subset of 27
genes was obtained by a step-by-step strategy by optimizing the
success rate. The DLDA-dissimilarity measure was then used to
predict the subtype (Supplementary Table S2).
For samples predicted as ccrcc1&4 (using the predictor men-
tioned above), a second centroid-based predictor was built to
assign each sample to one of the two subtypes ccrcc1 or ccrcc4. A
subset of the differentially expressed genes between ccrcc1 and
ccrcc4 subtypes was used. A gene was defined differentially
expressed between the two subtypes when the ANOVA P value
was<0.05 andwhen the absolute fold changewas>3. The optimal
subset of 8 genes was obtained by a step-by-step strategy by
optimizing the success rate. The DLDA-dissimilarity measure was
then used to predict the subtype.
The obtained centroid-based predictors were applied on two
public datasets: The Brannon expression dataset (GEO-website,
GSE33093; ref. 5) and TCGA dataset (6).
Use of immune metagenes
The datasets mentioned by Bindea and colleagues (21) were
downloaded and normalized separately using the fRMA Biocon-
ductor package. Cancer cell lines dataset GSE5720 was also
retrieved from Gene Expression Omnibus and normalized
using fRMA. Samples GSM133550, GSM133594, GSM133638,
GSM133657, which correspond respectively to ccRCC cell lines
ACHN, SN12C, UO-31, and Caki-1, were added. All probesets
identified included in the five metagenes used in our work (NK
CD56dim, Cytotoxic cells, T cells, B cells, macrophages) were
checked for expression by kidney cancer cell lines. One hundred
thirty-eightof142probesetswere completely specific andsensitive
to predict immune cell–type against ccRCC cell lines samples, and
134 of 142 probesets had a right-tailed t test P value < 0.05 when
compared with ccRCC cell lines samples. To compute average
metagene values in our dataset, log2 expression values for each
probesetswerefirstmapped to gene symbols using average expres-
sion of all the corresponding probesets, then this value was cen-
tered, and scaled across our dataset. Finally, the mean of all the
scaled expressions was taken to represent the signature.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue sections (5 mm)
were stained with an anti-CD8 (5.0 mg/mL; clone SP16; Spring-
bioscience) with an autostainer Link 48 (Dako) as previously
described (22). Deparaffinization, rehydration, and epitope
retrievalwereperformed inaPT-Link (Dako) inahighpHsolution
as described by the manufacturer. Tissue sections were first incu-
bated with anti-CD8 (SP16; Springbioscience) and posteriorly
withabiotin–streptavidin-coupledantibody.Revelationwasdone
with 3-amino-9-ethylcarbazole substrate (Vector Laboratories).
Results
Patient characteristics and clinical predictors of sunitinib
response
In our series of 121 patients, after a median follow-up of 55
months (range, 1.5–86), median PFS and OS were 13 and 27
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months, respectively.Forty-sevenpercentofpatientsexperienceda
complete or partial response (CR/PR), 36% stable disease
(SD), and 17% early PD following RECIST 1.0. By comparing
patients with extreme phenotype (CR/PR vs. PD), we identified
several clinical and biologic features associated with a poor suni-
tinib response: baseline neutrophilia, thrombocytosis, anemia,
sarcomatoid differentiation, synchronous metastases at initial
diagnosis, poorer ECOG-PS, Heng (23), and MSKCC scores (24,
25; Fig. 1A and B). However, in the overall series of patients, using
all the clinical, pathologic, andmolecular features and a variety of
predictive algorithms (PAM, DLDA, DQDA), supervised analyses
failed to identify robust factors predictive of sunitinib response
(Supplementary Table S5). As this result could be due to the
moleculardiversityof thetumors,weinvestigatedtherelationships
between ccRCC molecular subtypes and response to sunitinib.
Molecular subtypes and sunitinib response
Using the expression profiles of the 1% most variable probe
sets (n ¼ 324 representing 294 different genes) among the
whole series of tissues (53 ccRCCs, 6 NTs), we performed an
unsupervised consensus clustering analysis of our series. We
identified four robust subgroups of tumors, called ccrcc1 to
ccrcc4 (Fig. 2). In particular, ccrcc3 tumors included all NTs and
showed a transcriptomic signature closed to normal samples
(Fig. 2B and C).
To extend the molecular subtyping to a larger series, we built a
qRT-PCR 35-gene classifier (Supplementary Table S6), which
correctly classified 94% of the samples from the initial series in
ccrrc1–4, and was used to predict 47 additional ccRCC tumors.
In the series of 98 patients, nonresponders were enriched in
ccrcc1 (PD 22%) and ccrcc4 (27%) versus 3% and 0% in ccrcc2
and ccrcc3, respectively (Fig. 3A; Supplementary Table S7). In
contrast, responders were over-represented in ccrcc2 (PR/CR,
53%) and ccrcc3 (70%) compared with 41% and 21% in ccrcc1
and ccrcc4, respectively (P¼ 0.005; Fig. 3A; Supplementary Table
S7).Moreover, ccrcc1 and ccrcc4 tumors showed apoorer PFS (13,
8, 19, and 24 months, respectively; P ¼ 0.0003) and OS (24, 14,
35, and 50months, respectively; P¼ 0.001) comparedwith ccrcc2
and ccrcc3 tumors (Fig. 3B; Table 1; Supplementary Table S7).
Classification of the tumors recoded in ccrcc1&4 versus ccrcc2&3
was themost significant covariate in univariateCox analysiswith a
poorer PFS (P¼ 0.004) andOS (P¼ 0.0002). For themultivariate
analysis, in a first step, among all the factors that were associated
with PFS and OS in univariate analysis, we excluded those factors
that could be overlapping (Table 1). Finally, the following factors
were included in the multivariate analysis, both for PFS and OS:
IMDC score, the presence of bone metastases, the presence of
sarcomatoid dedifferentiation, 8q amplification, and the classi-
fication recoded as ccrcc2þ3versus ccrcc1þ4. It remained theonly
significant covariate in the multivariate Cox model for PFS (P ¼
0.017). In the multivariate Cox model for OS, the recoded
classification (P ¼ 0.0064) and the presence of bone metastasis
(P ¼ 0.049) remained as significant covariates (Fig. 3C).
Characterization of the m-ccRCC molecular subtypes
To better understand how each molecular subtype could
influence response to sunitinib, we characterized our cohort
for somatic mutations in PBRM1 and VHL genes (n ¼ 117
tumors), methylation profiling exploring 485,000 nucleotide
sites (n ¼ 102), and copy number targeting 731,442 genomic
loci (n ¼ 103). Transcriptome and methylome profiles of the
four subtypes were compared using pathway analysis methods,
and recurrent copy number aberrations were delimited from
the SNP profiles.
The ccrcc4 subtype demonstrated specific features at the path-
ologic levelwith frequent sarcomatoid differentiation and inflam-
mation (Fig. 4A; Table 2). Accordingly, pathway analysis of
transcriptome profiles identified an overexpression of genes relat-
ed to immune response, chemotaxis, and apoptosis (Fig. 4B).
These pathwayswere alsoderegulated at themethylome levelwith
hypomethylation of overexpressed genes which could be related
to the inflammatory and immune microenvironments character-
izing these tumors (Fig. 4C and Supplementary Table S8). The
ccrcc4 subtype had a high expression ofmarkers of inflammation,
such as members of the TNF and IRF families. The analysis of
cytokines revealed a strong expression of myeloid and T cells
homing factors and their corresponding receptors and Th-1–
related factors such as IFNg and IL12. The immune suppressive
Figure 1.
Clinical predictors of sunitinib response. Barplot of the clinical covariates associated with the two extreme responders: Partial or complete response (PR) versus PD.
SD samples were not used for the statistical analysis. Significant ANOVA or Fisher P values:  , P < 0.05; , P < 0.01; , P < 0.001.
Beuselinck et al.
Clin Cancer Res; 21(6) March 15, 2015 Clinical Cancer Research1332
IL10 as well as inhibitory receptors LAG3 and PD-1 (PDCD1) and
PD-1 ligands PD-L1 and PD-L2 were also highly expressed (Sup-
plementary Fig. S1). These results suggest that ccrcc4 tumors
display a strong inflammatory, Th1-oriented but suppressive
immune microenvironment. We then assessed the expression of
immune population-specific transcripts using gene signatures
previously published (Supplementary Fig. S2; ref. 21). ccrcc4
samples contained high amounts of B, T, and cytotoxic cells-
specific transcripts, but not of natural killer cells–specific tran-
scripts, suggesting that the cytotoxic signature in ccrcc4 is mostly
due to CD8þ T-cell infiltration. We analyzed 46 samples by
immunohistochemistry and confirmed a high infiltration of
CD8þ cells in ccrcc4 tumors (Supplementary Fig. S3). Sample
contamination with diploid cells was estimated to be slightly
higher in ccrcc4 tumors, which could reflect immune infiltration
(Supplementary Fig. S5C).
Overall, 45% of the tumors were VHL-mutated and 32%
PBRM1-mutated. Whereas rare mutations in VHL and PBRM1
were found in ccrcc4 tumors, they were frequent in ccrcc1 and
ccrcc2 tumors but without relationship with sunitinib response
(Fig. 4A and Table 2).
At a global methylation level, ccrcc1/ccrcc4 tumors showed
more hypermethylated probes in CpG islands compared with
the other subtypes (Supplementary Fig. S4A). Pathway
analysis of the related hypermethylated genes showed a
strong enrichment of polycomb targets (hypergeometric test,
P < 8e–147), and corresponding genes (PRC2, SUZ12, and
H3K27m3) were found downexpressed (Supplementary Fig.
S4B), suggesting a stem-cell phenotype for these two subtypes.
The ccrcc1/ccrcc4 subtypes were indeed less differentiated,
displaying 76% of Fuhrman grade 4 compared with 56% in
ccrcc2/ccrcc3 tumors.
The ccrcc4 subtype showed several characteristic copy-num-
ber aberrations, the most significant being 2p12, 2p22.3, and
8q21.13 amplifications (Fig. 4D; Supplementary Fig. S5; Sup-
plementary Table S9), and both ccrcc1 and ccrcc4 subtypes
overexpressed MYC targets (Fig. 4B). Amplification in the
upstream region of MYC was found in >40% of ccrcc1 and
ccrcc4 tumors compared with <22% in the other subtypes. Also,
a CpG island was hypomethylated in the body gene of MYC in
ccrcc1/ccrcc2/ccrcc4 tumors as compared with ccrcc3/NTs
(ANOVA P < 0.0001), suggesting that both DNA copy number
and methylation aberrations could contribute to MYC over-
expression in the ccrcc1 and ccrcc4 subtypes (Supplementary
Fig. S6).
Finally, the expression profile of ccrcc3 samples was similar to
that of NTs concerning metabolic pathways and transporter
activities, consistent with the cluster_3 described by Brannon and
colleagues (ref. 5; Fig. 4B). ccrcc3 tumors also showed a methyl-
ation profile similar to that of NTs (Supplementary Fig. S4C).
Despite the "normal-like" characteristics of ccrcc3 tumors, path-
ologic review confirmed the tumoral nature of these samples and
Figure 2.
Identification of four robust subgroups
through an unsupervised consensus
clustering analysis of expression data.
A, coclassification matrix of the 59
RCC samples. Blue ¼ low
coclassification and red ¼ high
coclassification. B, sample partition for
K¼ 2 clusters toK¼4 clusters. C, gene
expression profile heatmap of the
most variant probe sets ordered by
subtype. Blue ¼ low expression level
and red ¼ high expression level.
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their clear cell histology. The ccrcc2 subtype was not characterized
by specific pathways; it always showed an intermediate expression
signature, comprised between ccrcc3 and ccrcc1/ccrcc4–related
profiles (Fig. 4B). ccrcc2 tumors showed the highestmutation rate
for VHL. In ccrcc2 tumors, the "cellular response to hypoxia"
pathway was less activated than in the ccrcc1/ccrcc4 subtypes
(Fig. 4B).
Based on these molecular characteristics, we renamed our
subtypes as follows: ccrcc1 ¼ "c-myc-up," ccrcc2 ¼ "classical,"
ccrcc3 ¼ "normal-like," and ccrcc4 ¼ "c-myc-up and immune-
up"(Table 2).
Validation using the TCGA dataset
We further predicted our four subtypes in the public TCGA
samples (Supplementary Fig. S7; ref. 6)with our 35-gene classifier
(Supplementary Table S6). Like in our series, ccrcc3 tumors
showed "normal-like" transcriptome and methylome profiles.
Somatic PBRM1 mutations were most frequently identified in
ccrcc1/ccrcc2 tumors but rarely found in ccrcc3/ccrcc4 tumors. In
both series, somatic VHL mutations were more frequently dis-
tributed in ccrcc1/ccrcc2 tumors. The BAP1 and SETD2mutations
(data not available in our series) also showed association with the
molecular subtypes: BAP1wasmostmutated in the ccrcc4 tumors
(P value ¼ 0.0098) and SETD2 was most mutated in the ccrcc1
tumors (P value ¼ 0.06). At a methylation level, in the TCGA
samples, ccrcc1/ccrcc4 tumors also showed more hypermethy-
lated probes in CpG islands compared with the other subtypes.
Pathways involved in immune response and mitotic cell cycle
were activated in ccrcc4 tumors, meanwhile in ccrcc3 tumors,
pathways involved in hypoxia were not activated. Finally, in the
TCGA cohort, 2p11.2, 8q12.1, and 8q24.3 amplifications were
mostly found in ccrcc1/ccrcc4 tumors. Supplementary Fig. S8
shows the survival analysis according to our classification:
ccrcc2/ccrcc3 tumors display the best survival, ccrcc1 tumors an
Figure 3.
Correlation of the four molecular
subgroups andoutcomeon sunitinib in
the metastatic setting. A, association
of sunitinib response with the
unsupervised subgroups ccrcc1 to
ccrcc4 (left) and the Brannon
subgroups (right). The P values result
from Fisher exact tests. B, association
of the four unsupervised subgroups
with PFS (left) and OS (right). Log-
rank P values are on the top right.
C, forest plots of the multivariate Cox
models for PFS and OS.
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intermediate survival, and ccrcc4 tumors the poorest survival (P <
0.0001).
Discussion
Our multi-omics analysis revealed that molecular tumor sub-
types are germane to predict response, PFS, and OS, in patients
with m-ccRCC treated with sunitinib. We identified 4 robust
molecular subgroups of ccRCCs based onmRNA expression data.
ccrcc3 ("normal-like") and ccrcc2 tumors ("classical") showed
better sunitinib responses than ccrcc1 ("c-myc-up") and ccrcc4
tumors ("c-myc-up and immune-up"). The ccrcc4 subtype was
associated with the poorest sunitinib response. Subtype classifi-
cation was the only significant covariate in multivariate analyses
for PFS and OS. Survival was significantly longer for ccrcc2/ccrcc3
compared with ccrcc1/ccrcc4.
Comparison with previous ccRCC molecular classifications
showed a high correlation of our four ccrcc groups with the three
groups ccA, ccB, and cluster_3 described by Brannon and collea-
gues (4, 5; Supplementary Table S10). In particular, ccrcc3 tumors
shared several characteristics of cluster_3 (5); it included all NTs
and showed a transcriptomic signature closed to normal samples
(Fig. 2B and C). Although the series of Brannon and colleagues
and the TCGA included both patients that were cured with
nephrectomy alone as well as patients that eventually reached
the metastatic setting, whereas in our series, only patients with
metastatic diseasewere included, our subgroups are tightly related
to the previously identified classification with an over-represen-
tation of the poor-prognosis ccB group, and its refinement in
two subgroups, ccrcc1 and ccrcc4. Subtypeswere identifiedusing a
35-gene signature that could be useful in future tumor screening.
Given the important and significant difference in RR, this classi-
fication has both predictive and prognostic potential in sunitinib-
treated patients with m-ccRCC.
The incidence of VHL mutations was lower than the reported
incidence in literature of 55% to 60% in sporadic ccRCCs. VHL
disease–associated ccRCCs seem to grow more slowly and are
associated with an overall better prognosis than sporadic ccRCCs.
Sporadic ccRCCs that lack functional VHL protein might, there-
fore, be expected to have a better prognosis than sporadic ccRCCs
resulting from VHL-independent mechanisms of pathogenesis.
Some studies seem to support this hypothesis (26, 27), although
Table 1. Univariate Cox analyses of OS and PFS
Univariate Multivariate
Annotation Value HR (95% CI) P value
Log-rank




Classification ccrcc2 0.60 (0.34–1.1) 0.08 0.001
ccrcc3 0.56 (0.24—1.3) 0.2
ccrcc4 2.31 (1.1–4.7) 0.02
Recoded classification ccrcc1&4 vs. ccrcc2&3 0.49 (0.3–0.8) 0.004 0.004 0.42 (0.21—0.86) 0.017 0.0001
Baseline neutrophil levels >4,500/mm3 2.14 (1.4–3.3) 0.0004 0.0003
Sarcomatoid dedifferentiation
in tumor (%)
— 1-1.029 0.007 0.005 1.00 (0.98—1.01) 0.89
Fuhrman grade — 1.55 (0.99—2.4) 0.05 0.05
ECOG-PS — 1.54 (1.2—2) 0.001 0.001
Amp_8q21.13 Y 1.99 (1.2–3.2) 0.004 0.003 1.41 (0.72—2.78) 0.31
Bone metastasis — 1.42 (0.92—2.2) 0.1 0.1 1.05 (0.58—1.90) 0.86
IMDC (HENG) score Intermediate 2.46 (1.1–5.4) 0.03 0.004 1.73 (0.64—4.64) 0.28
Poor 3.83 (1.7–8.9) 0.002 3.76 (1.26–11.22) 0.017
MSKCC score Intermediate 2.62 (1.2–5.8) 0.02 0.04
Poor 2.65 (1.1–6.2) 0.02
OS
Classification ccrcc2 0.45 (0.25—0.8) 0.007 0.0003
ccrcc3 0.55 (0.24—1.3) 0.2
ccrcc4 1.93 (0.97—3.8) 0.06
Recoded classification ccrcc1&4 vs. ccrcc2&3 0.40 (0.24—0.66) 0.0004 0.0002 0.38 (0.19—0.76) 0.0064 0.00003
Baseline neutrophil levels > 4,500/mm3 1.60 (1–2.5) 0.04 0.04
Sarcomatoid dedifferentiation
in tumor (%)
— 1-1.031 0.0009 0.0005 1.01 (0.99—1.03) 0.17
Fuhrman grade — 1.95 (1.2–3.2) 0.008 0.007
ECOG-PS — 1.41 (1.1–1.8) 0.01 0.01
Amp_8q21.13 Y 1.99 (1.2–3.2) 0.004 0.003 1.21 (0.62—2.35) 0.58
Bone metastasis — 1.94 (1.2–3.1) 0.004 0.003 1.81 (1.00—3.28) 0.049
IMDC (HENG) score Intermediate 2.67 (1.1–6.7) 0.04 0.005 1.67 (0.56—4.91) 0.35
Poor 4.34 (1.6–12) 0.003 2.44 (0.71–8.36) 0.16
MSKCC score Intermediate 3.64 (1.4–9.3) 0.007 0.02
Poor 3.53 (1.3–9.6) 0.01
NOTE: Univariatemodelswere performedon all the pathologic and clinical covariates. Only significant covariates in anyof the two analyzes are indicated. Continuous
variables are annotated "—" in the "value" column. For the multivariate analysis, in a first step, among all the factors that were associated with PFS and OS in
univariate analysis, we excluded those factors that could be overlapping. For instance, IMDC (Heng) score and MSKCC score are redundant. We preferred
IMDC (Heng) score, because the P values were more significant for PFS and OS in univariate analysis. As ECOG-PS and neutrophil count are part of the IMDC
(Heng) score, theywere excluded. As all tumorswith sarcomatoid dedifferentiationwere classified Fuhrmangrade4,weonly retained sarcomatoid dedifferentiation.
As a consequence, the following factors were included in the multivariate analysis, both for PFS and for OS: IMDC (Heng) score, the presence of bone metastases,
the presence of sarcomatoid dedifferentiation, 8q amplification, and the classification recoded as ccrcc2þ3 versus ccrcc 1þ4.
Abbreviation: CI, confidence interval.
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others have foundno associationbetween the presence or absence
of VHL alterations and prognosis or adverse clinical and patho-
logic features.
The ccrcc1/ccrcc4 subtypes, which were more closely linked
with nonresponders to sunitinib, shared common molecular
characteristics such as upregulation of MYC targets or a hyper-
methylated status strongly correlated with a polycomb stem-cell
phenotype.
However, ccrcc4 tumors showed specific pathologic features
such as a more inflammatory and sarcomatoid phenotype, an
upregulation of cellular immune pathways, and an omnipresent
8q21.13 amplification. These findings are consistent with several
publications showing the negative impact on outcome of an
elevated baseline C-reactive protein level, a marker of inflamma-
tion, and of the presence of sarcomatoid differentiation in m-
ccRCC treated with anti-VEGFR TT (28–31).
Inflammation is a double-edged sword in cancer immunology.
It can both fuel tumor cells growth and reinforce antitumor
immunity. Consistently with our observations, extensive infiltra-
tion of CD8þ T cells in pulmonary metastases in patients with m-
ccRCC was associated with a shorter OS (22). Nonetheless,
infiltrating CD8þ T cells are likely suppressed in this context, due
to regulatory cytokines (IL10, TGFB1) and T-cell immunosup-
pressive molecules [PD-L1 (CD274)] highly expressed in ccrcc4.
ccRCCs are extensively infiltrated with myeloid-derived suppres-
sor cells (32), which are likely to arise in a hypoxic environment
and participate to T-cell suppression. These cells, as well as
regulatory T cells, whose markers (FOXP3, IL10, and TGFb) are
also highly expressed in ccrcc4, have also been reported to allow
escape from sunitinib treatment (33, 34).
Integrative analyses of the different omic experiments sug-
gested a possible gradient of tumor progression in the following
order: normal samples/ccrcc3/ccrcc2/ccrcc1/ccrcc4. We observed
a metabolism switch with increasing deregulation along the
ordered subtypes; similar results are obtained for the polycomb
stem-cell phenotypes, the hypermethylated profile or the MYC
target activation (Supplementary Fig. S9). These features fit the
transcriptional and epigenetic sequential changes responsible for
cellular reprogramming leading to acquired pluripotency by
fibroblasts (35): apoptosis blockade, cell cycle activation, meta-
bolic switch, polycomb stem-cell phenotype with the involve-
ment of MYC in this cell reprogramming. Inversely, activation of
the immune pathway in ccrcc4 tumors seemed more linked to a
switch on/off than to a gradient. Similarly, in ccrcc4, few VHL/
Figure 4.
Clinical and molecular characteristics of the four clear cell RCC subgroups. A, barplot of the pathologic features and the incidence of VHL and PBRM1 mutations
associated with the four unsupervised subgroups (ccrcc1 to ccrcc4). Pathologic features were analyzed through microscopy on hematoxylin and eosin–stained
slides. Tumors were screened for VHL and PBRM1mutations using direct sequencing. Significant ANOVA or Fisher P values:  , P < 0.05;  , P < 0.01. B, representation
of the mean expression level of differentially regulated pathways between the four subgroups. Pathways are sorted by the difference between the ccrcc4 subgroup
and the normal samples (NL). For a given pathway, samples are sorted by mean expression value. C, representation of the rate of upregulated genes within
hypomethylated genes (black) and of the rate of downregulated genes within hypermethylated genes (gray), for each pathway. Pathways are sorted by
the difference between the rates of up- and downregulated genes in the subgroup. D, barplot of the chromosomal aberrations identified by the GISTIC algorithm
and associated with the ccrcc4 subtype. Significant Fisher P values are denoted as  , P < 0.001.
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PBRM1 mutations were detected, indicating that probably other
gene alterations might be involved in the pathogenesis of ccrcc4
tumors.
Hypoxia pathways are not activated in ccrcc3 tumors and less
activated in ccrcc2 tumors than in resistant ccrcc1/ccrcc4 tumors
(Fig. 4B). Hypoxia is associated with tumor aggressiveness
through higher HIF levels and expression of genes involved in
tumor proliferation, vasculature, invasion, and metastatic spread
leading to a poor prognosis. Through the reduction and normal-
ization of blood vessels, anti-VEGF TT leads to better oxygen
delivery in the tumor. Thus, lowering hypoxia might be an
important part of the mechanism of action of anti-VEGF TT.
However, tumor hypoxia was recently assessed before the start
and after one month of sunitinib by a PET-CT scan with 18F-
fluoromisonidazole, which accumulates in hypoxic cells. Patients
with initially hypoxic targets had shorter PFS than patients with
nonhypoxic targets (36). Thus, the balance of neoangiogenesis
versus hypoxia could be a major trigger of response to anti-VEGF
TT (37).
In a first step, as we worked on a limited number of patients,
our findings should be validated in an independent patient
cohort. Once validated, this molecular subtyping of tumors
could probably help treatment personalization. Because
patients with ccrcc4 tumors have a short PFS under sunitinib
treatment, hypomethylating agents targeting epigenetic defects
(38) or immunomodulatory antibodies (39) should be pref-
erentially tested in this subgroup of patients (40). Moreover, as
even in the poor-prognosis ccrcc4 subgroup, 20% of the
patients experienced a PR, and as a placebo-treated subgroup
of patients is not available for comparison, our classification
does not permit us to preclude any subgroup of patients from
treatment with sunitinib. Further validation of these findings is
warranted in future clinical trials integrating molecular sub-
typing in their design.
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